+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Not Verified

Blood Cancer Quality of Life Grant

The Leukemia & Lymphoma Society of Canada

Canadian researchers are invited to submit proposals to The Leukemia & Lymphoma Society of Canada (LLSC)'s Blood Cancer Quality of Life Grant Program Competition. This is a two-year grant designed to provide funding up to a maximum of $75,000 per year for two years.

The intent of this funding opportunity is to support new research designed to address quality of life challenges experienced by patients and their caregivers affected by blood cancers from the time of their diagnosis until entry into end-of-life care.

Diverse study types will be considered, including both interventional (e.g., feasibility, pilot, RCTs) and non-interventional studies (e.g., cohort, case-control, cross-sectional, measure development). Studies may include the use of quantitative, qualitative and mixed methods approaches to data collection and analysis. Areas of focus may include, but are not limited to:

Interventions of the emotional effects of cancer, including fear of recurrence
Interventions or understanding of the acute and long term effects, and late effects
Vocational, finances and return to work
Managing the chronic effects of blood cancers
Development of quality of life measures specific to blood cancers
Interventions to optimize functioning in daily life
Survivorship models of care
Quality of life of specific populations (e.g., AYA, older adults, pediatrics, caregivers)

Key dates for 2025-2026

Call for Proposals - October 30, 2025
Letter of Intent (LOI) deadline - December 4, 2025, 4 pm ET
Notification of Full Application invite - December 2025
Full Application deadline - February 11, 2026, 4 pm ET
Review Panel Meeting - May 2026
Notification of Awards - Fall 2026
Award Start Date - November 2026

AI Based Application Success Predictor

1. Direct Relevance to Blood Cancers

The strongest predictor is focusing specifically on hematologic malignancies:

Leukemias (ALL, AML, CLL, CML)

Lymphomas (Hodgkin & Non-Hodgkin)

Myeloma & Waldenström’s macroglobulinemia

MDS, MPNs & other marrow failure states

Pediatric and AYA cancers (high priority)

High-value themes:

Drug resistance & relapse prevention

MRD and early detection biomarkers

Immunotherapy (CAR-T, BiTEs, NK, vaccines)

Targeted therapies (BCL2, FLT3, IDH1/2, BTK inhibitors)

Genomic & epigenetic vulnerabilities

High-risk or underserved populations

Survivorship toxicities and late effects

❗ Generic oncology proposals without a hematologic cancer focus are not competitive.

2. Strong Alignment With the Mechanism

Each mechanism has distinct expectations:

Mechanism	Ideal Applicant	What Reviewers Look For
Early-Career & Fellowship Awards	New investigators	Mentorship + trajectory + institutional support
Translational & Clinical Grants	Mid-career and clinician-scientists	Path to clinical adoption + patient access
Pediatric & Survivorship Grants	Teams with pediatric patient networks	Impact on cure rates, late effects, QoL

Predictor: Match career stage, project maturity, and disease focus to the program.

3. Canadian Patient Impact

LLSC is very Canada-focused. Competitive proposals show:

Direct benefit for Canadian patients

Use of national datasets, biobanks, or BMT networks

Cross-province collaboration and site access

Patient partner involvement and knowledge translation plans

Predictor: Clearly state why this matters to Canadians with blood cancers.

4. Feasible, Translational Pathway

LLSC prioritizes near-term clinical relevance, including:

IND- or trial-ready therapeutics

Biomarkers aligned to treatment decisions

Real-world health system research

Approaches that reduce treatment burden and late toxicity

Predictor: The proposal must articulate how results change patient care.

5. Strong Preliminary Data

Even exploratory grants typically benefit from:

Proof-of-concept experiments

Early clinical feasibility or pilot signals

Validated assays or analytic pipelines

Demonstrated access to required data or samples

Predictor: Preliminary evidence is one of the biggest success drivers.

6. Use of Relevant Human Models / Data

Highly scoring proposals employ:

Primary patient samples

Blood cancer cell lines and PDX models

BMT cohorts or immunotherapy datasets

Clinical MRD testing and multi-omics profiles

Predictor: Human relevance strengthens rigor and impact.

7. Strong Investigator Track Record

For faculty-level grants, reviewers emphasize:

Publications in hematologic malignancies

Demonstrated independence and scientific direction

Successful delivery of prior projects

Leadership in collaborative research

Predictor: A trajectory toward national or global leadership in hematologic oncology.

8. Multidisciplinary Collaboration

Partnerships are viewed very positively:

Clinician–scientist + immunology/bioinformatics combinations

Pediatric oncology networks

Multi-site clinical projects across Canada

Data-science or imaging experts

Predictor: Collaboration amplifies feasibility and generalizability.

9. Clear, Focused Aims & Milestones

LLSC grants are milestone-driven. Competitive proposals show:

2–3 sharply defined aims

Quantifiable outcomes

Strong stats plan and risk-mitigation

Logical path to future funding (Canadian or international)

Predictor: Tight scope = high feasibility score.

10. Strong Writing & Compliance

Winning applications are:

Concise, visually supported, and logically structured

Explicit about impacts on survival and quality of life

Fully compliant with format, eligibility, and budgeting guidelines

Predictor: Clear communication improves scientific and significance scoring.

🏆 Summary — LLSC Success Predictors

Predictor	Why It Matters
Blood cancer specificity	Core mission
Mechanism alignment	Proper reviewer expectations
Canadian patient impact	Major priority
Translational feasibility	Drives clinical benefit
Preliminary data	Demonstrates feasibility
Human samples / cohorts	Stronger relevance
Investigator track record	Execution confidence
Collaboration	Broadens impact
Focused aims	Within scope & timeline
Excellent writing	Higher reviewer enthusiasm

Specialties

Cancer

Eligibility Requirements

Researchers in any field are encouraged to apply

Sponsor Details

Sponsor Institute/Organizations: The Leukemia & Lymphoma Society of Canada

Sponsor Type: Corporate/Non-Profit

Address: 2 Lansing Square, Suite 601 Toronto, ON M2J 4P8

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity